Insider Transactions in Q1 2023 at Graybug Vision, Inc. (GRAY)
Insider Transaction List (Q1 2023)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 23
2023
|
Christina Ackermann Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
Mar 23
2023
|
Eric Bjerkholt |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
Mar 23
2023
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,677
-26.41%
|
$63,385
$5.5 P/Share
|
Mar 23
2023
|
Robert S Breuil Chief Financial Officer |
BUY
Sale (or disposition) back to the issuer
|
Direct |
36,657
+43.3%
|
-
|
Mar 23
2023
|
Julia Marie Eastland Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
Mar 23
2023
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
20,383
-18.34%
|
$101,915
$5.5 P/Share
|
Mar 23
2023
|
Frederic Guerard |
BUY
Sale (or disposition) back to the issuer
|
Direct |
83,705
+42.97%
|
-
|
Mar 23
2023
|
Dirk Sauer Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
Mar 23
2023
|
Christy L Shaffer Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
Mar 23
2023
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,901
-38.18%
|
$89,505
$5.5 P/Share
|
Mar 23
2023
|
Parisa Zamiri Chief Medical Officer |
BUY
Sale (or disposition) back to the issuer
|
Direct |
42,771
+47.71%
|
-
|
Mar 20
2023
|
Sanderling Venture Partners Vi LP |
BUY
Grant, award, or other acquisition
|
Indirect |
936,656
+50.0%
|
-
|
Mar 20
2023
|
Sanderling Venture Partners Vi LP |
BUY
Grant, award, or other acquisition
|
Direct |
703,388
+50.0%
|
-
|
Mar 20
2023
|
Valence Investments Spv Iv LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
382,337
+50.0%
|
-
|
Mar 20
2023
|
Valence Investments Spv Iv LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
356,989
+50.0%
|
-
|
Mar 20
2023
|
Fred A Middleton |
BUY
Grant, award, or other acquisition
|
Indirect |
1,648,220
+50.0%
|
-
|
Mar 20
2023
|
Kenneth A. Stauderman Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,944
+50.0%
|
-
|
Mar 20
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
749,987
+50.0%
|
-
|
Mar 20
2023
|
Robert N Wilson |
BUY
Grant, award, or other acquisition
|
Direct |
181,655
+50.0%
|
-
|
Mar 20
2023
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
739,326
+50.0%
|
-
|
Mar 14
2023
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-1.06%
|
$0
$0.58 P/Share
|
Mar 14
2023
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.96%
|
-
|
Mar 03
2023
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,894
-24.07%
|
$0
$0.57 P/Share
|
Mar 03
2023
|
Parisa Zamiri Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
120,655
+40.37%
|
-
|
Mar 03
2023
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
89,344
-18.89%
|
$0
$0.57 P/Share
|
Mar 03
2023
|
Frederic Guerard |
BUY
Exercise of conversion of derivative security
|
Direct |
315,496
+40.01%
|
-
|
Mar 03
2023
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
49,434
-23.73%
|
$0
$0.57 P/Share
|
Mar 03
2023
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
121,217
+36.79%
|
-
|